Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant

Sonali M. Smith, Koen van Besien, Jeanette Carreras, Asad Bashey, Mitchell S. Cairo, Cesar O. Freytes, Robert Peter Gale, Gregory A. Hale, Brandon Hayes-Lattin, Leona A. Holmberg, Armand Keating, Richard T. Maziarz, Philip L. McCarthy, Willis H. Navarro, Santiago Pavlovsky, Harry C. Schouten, Matthew Seftel, Peter H. Wiernik, Julie Marie Vose, Hillard M. LazarusParameswaran Hari

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

We determined treatment-related mortality, progression-free survival (PFS), and overall survival (OS) after a second autologous HCT (HCT2) for patients with lymphoma relapse after a prior HCT (HCT1). Outcomes for patients with either Hodgkin lymphoma (HL, n = 21) or non-Hodgkin lymphoma (NHL, n = 19) receiving HCT2 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) were analyzed. The median age at HCT2 was 38 years (range: 16-61) and 22 (58%) patients had a Karnofsky performance score <90. HCT2 was performed >1 year after HCT1 in 82%. The probability of treatment-related mortality at day 100 was 11% (95% confidence interval [CI], 3%-22%). The 1-, 3-, and 5-year probabilities of PFS were 50% (95% CI, 34%-66%), 36% (95% CI, 21%-52%), and 30% (95% CI, 16%-46%), respectively. Corresponding probabilities of survival were 65% (95% CI, 50%-79%), 36% (95% CI, 22%-52%), and 30% (95% CI, 17%-46%), respectively. At a median follow-up of 72 months (range: 12-124 months) after HCT2, 29 patients (73%) have died, 18 (62%) secondary to relapsed lymphoma. The outcomes of patients with HL and NHL were similar. In summary, this series represents the largest reported group of patients with relapsed lymphomas undergoing SCT2 following failed SCT1, and with long-term follow-up. Our series suggests that SCT2 is feasible in patients relapsing after prior HCT1, with a lower treatment-related mortality than that reported for allogeneic transplant in this setting. HCT2 should be considered for patients with relapsed HL or NHL after HCT1 without alternative allogeneic stem cell transplant options.

Original languageEnglish (US)
Pages (from-to)904-912
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume14
Issue number8
DOIs
StatePublished - Aug 1 2008

Fingerprint

Autografts
Stem Cell Transplantation
Lymphoma
Confidence Intervals
Transplants
Disease-Free Survival
Mortality
Survival
Hodgkin Disease
Non-Hodgkin's Lymphoma
Stem Cells
Therapeutics
Bone Marrow
Recurrence
Research

Keywords

  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma
  • Second autologous transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Smith, S. M., van Besien, K., Carreras, J., Bashey, A., Cairo, M. S., Freytes, C. O., ... Hari, P. (2008). Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant. Biology of Blood and Marrow Transplantation, 14(8), 904-912. https://doi.org/10.1016/j.bbmt.2008.05.021

Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant. / Smith, Sonali M.; van Besien, Koen; Carreras, Jeanette; Bashey, Asad; Cairo, Mitchell S.; Freytes, Cesar O.; Gale, Robert Peter; Hale, Gregory A.; Hayes-Lattin, Brandon; Holmberg, Leona A.; Keating, Armand; Maziarz, Richard T.; McCarthy, Philip L.; Navarro, Willis H.; Pavlovsky, Santiago; Schouten, Harry C.; Seftel, Matthew; Wiernik, Peter H.; Vose, Julie Marie; Lazarus, Hillard M.; Hari, Parameswaran.

In: Biology of Blood and Marrow Transplantation, Vol. 14, No. 8, 01.08.2008, p. 904-912.

Research output: Contribution to journalArticle

Smith, SM, van Besien, K, Carreras, J, Bashey, A, Cairo, MS, Freytes, CO, Gale, RP, Hale, GA, Hayes-Lattin, B, Holmberg, LA, Keating, A, Maziarz, RT, McCarthy, PL, Navarro, WH, Pavlovsky, S, Schouten, HC, Seftel, M, Wiernik, PH, Vose, JM, Lazarus, HM & Hari, P 2008, 'Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant', Biology of Blood and Marrow Transplantation, vol. 14, no. 8, pp. 904-912. https://doi.org/10.1016/j.bbmt.2008.05.021
Smith, Sonali M. ; van Besien, Koen ; Carreras, Jeanette ; Bashey, Asad ; Cairo, Mitchell S. ; Freytes, Cesar O. ; Gale, Robert Peter ; Hale, Gregory A. ; Hayes-Lattin, Brandon ; Holmberg, Leona A. ; Keating, Armand ; Maziarz, Richard T. ; McCarthy, Philip L. ; Navarro, Willis H. ; Pavlovsky, Santiago ; Schouten, Harry C. ; Seftel, Matthew ; Wiernik, Peter H. ; Vose, Julie Marie ; Lazarus, Hillard M. ; Hari, Parameswaran. / Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant. In: Biology of Blood and Marrow Transplantation. 2008 ; Vol. 14, No. 8. pp. 904-912.
@article{1de1954bf96a4420b2f0dbc40cc827a1,
title = "Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant",
abstract = "We determined treatment-related mortality, progression-free survival (PFS), and overall survival (OS) after a second autologous HCT (HCT2) for patients with lymphoma relapse after a prior HCT (HCT1). Outcomes for patients with either Hodgkin lymphoma (HL, n = 21) or non-Hodgkin lymphoma (NHL, n = 19) receiving HCT2 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) were analyzed. The median age at HCT2 was 38 years (range: 16-61) and 22 (58{\%}) patients had a Karnofsky performance score <90. HCT2 was performed >1 year after HCT1 in 82{\%}. The probability of treatment-related mortality at day 100 was 11{\%} (95{\%} confidence interval [CI], 3{\%}-22{\%}). The 1-, 3-, and 5-year probabilities of PFS were 50{\%} (95{\%} CI, 34{\%}-66{\%}), 36{\%} (95{\%} CI, 21{\%}-52{\%}), and 30{\%} (95{\%} CI, 16{\%}-46{\%}), respectively. Corresponding probabilities of survival were 65{\%} (95{\%} CI, 50{\%}-79{\%}), 36{\%} (95{\%} CI, 22{\%}-52{\%}), and 30{\%} (95{\%} CI, 17{\%}-46{\%}), respectively. At a median follow-up of 72 months (range: 12-124 months) after HCT2, 29 patients (73{\%}) have died, 18 (62{\%}) secondary to relapsed lymphoma. The outcomes of patients with HL and NHL were similar. In summary, this series represents the largest reported group of patients with relapsed lymphomas undergoing SCT2 following failed SCT1, and with long-term follow-up. Our series suggests that SCT2 is feasible in patients relapsing after prior HCT1, with a lower treatment-related mortality than that reported for allogeneic transplant in this setting. HCT2 should be considered for patients with relapsed HL or NHL after HCT1 without alternative allogeneic stem cell transplant options.",
keywords = "Hodgkin lymphoma, Non-Hodgkin lymphoma, Second autologous transplant",
author = "Smith, {Sonali M.} and {van Besien}, Koen and Jeanette Carreras and Asad Bashey and Cairo, {Mitchell S.} and Freytes, {Cesar O.} and Gale, {Robert Peter} and Hale, {Gregory A.} and Brandon Hayes-Lattin and Holmberg, {Leona A.} and Armand Keating and Maziarz, {Richard T.} and McCarthy, {Philip L.} and Navarro, {Willis H.} and Santiago Pavlovsky and Schouten, {Harry C.} and Matthew Seftel and Wiernik, {Peter H.} and Vose, {Julie Marie} and Lazarus, {Hillard M.} and Parameswaran Hari",
year = "2008",
month = "8",
day = "1",
doi = "10.1016/j.bbmt.2008.05.021",
language = "English (US)",
volume = "14",
pages = "904--912",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant

AU - Smith, Sonali M.

AU - van Besien, Koen

AU - Carreras, Jeanette

AU - Bashey, Asad

AU - Cairo, Mitchell S.

AU - Freytes, Cesar O.

AU - Gale, Robert Peter

AU - Hale, Gregory A.

AU - Hayes-Lattin, Brandon

AU - Holmberg, Leona A.

AU - Keating, Armand

AU - Maziarz, Richard T.

AU - McCarthy, Philip L.

AU - Navarro, Willis H.

AU - Pavlovsky, Santiago

AU - Schouten, Harry C.

AU - Seftel, Matthew

AU - Wiernik, Peter H.

AU - Vose, Julie Marie

AU - Lazarus, Hillard M.

AU - Hari, Parameswaran

PY - 2008/8/1

Y1 - 2008/8/1

N2 - We determined treatment-related mortality, progression-free survival (PFS), and overall survival (OS) after a second autologous HCT (HCT2) for patients with lymphoma relapse after a prior HCT (HCT1). Outcomes for patients with either Hodgkin lymphoma (HL, n = 21) or non-Hodgkin lymphoma (NHL, n = 19) receiving HCT2 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) were analyzed. The median age at HCT2 was 38 years (range: 16-61) and 22 (58%) patients had a Karnofsky performance score <90. HCT2 was performed >1 year after HCT1 in 82%. The probability of treatment-related mortality at day 100 was 11% (95% confidence interval [CI], 3%-22%). The 1-, 3-, and 5-year probabilities of PFS were 50% (95% CI, 34%-66%), 36% (95% CI, 21%-52%), and 30% (95% CI, 16%-46%), respectively. Corresponding probabilities of survival were 65% (95% CI, 50%-79%), 36% (95% CI, 22%-52%), and 30% (95% CI, 17%-46%), respectively. At a median follow-up of 72 months (range: 12-124 months) after HCT2, 29 patients (73%) have died, 18 (62%) secondary to relapsed lymphoma. The outcomes of patients with HL and NHL were similar. In summary, this series represents the largest reported group of patients with relapsed lymphomas undergoing SCT2 following failed SCT1, and with long-term follow-up. Our series suggests that SCT2 is feasible in patients relapsing after prior HCT1, with a lower treatment-related mortality than that reported for allogeneic transplant in this setting. HCT2 should be considered for patients with relapsed HL or NHL after HCT1 without alternative allogeneic stem cell transplant options.

AB - We determined treatment-related mortality, progression-free survival (PFS), and overall survival (OS) after a second autologous HCT (HCT2) for patients with lymphoma relapse after a prior HCT (HCT1). Outcomes for patients with either Hodgkin lymphoma (HL, n = 21) or non-Hodgkin lymphoma (NHL, n = 19) receiving HCT2 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) were analyzed. The median age at HCT2 was 38 years (range: 16-61) and 22 (58%) patients had a Karnofsky performance score <90. HCT2 was performed >1 year after HCT1 in 82%. The probability of treatment-related mortality at day 100 was 11% (95% confidence interval [CI], 3%-22%). The 1-, 3-, and 5-year probabilities of PFS were 50% (95% CI, 34%-66%), 36% (95% CI, 21%-52%), and 30% (95% CI, 16%-46%), respectively. Corresponding probabilities of survival were 65% (95% CI, 50%-79%), 36% (95% CI, 22%-52%), and 30% (95% CI, 17%-46%), respectively. At a median follow-up of 72 months (range: 12-124 months) after HCT2, 29 patients (73%) have died, 18 (62%) secondary to relapsed lymphoma. The outcomes of patients with HL and NHL were similar. In summary, this series represents the largest reported group of patients with relapsed lymphomas undergoing SCT2 following failed SCT1, and with long-term follow-up. Our series suggests that SCT2 is feasible in patients relapsing after prior HCT1, with a lower treatment-related mortality than that reported for allogeneic transplant in this setting. HCT2 should be considered for patients with relapsed HL or NHL after HCT1 without alternative allogeneic stem cell transplant options.

KW - Hodgkin lymphoma

KW - Non-Hodgkin lymphoma

KW - Second autologous transplant

UR - http://www.scopus.com/inward/record.url?scp=47249135075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249135075&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2008.05.021

DO - 10.1016/j.bbmt.2008.05.021

M3 - Article

C2 - 18640574

AN - SCOPUS:47249135075

VL - 14

SP - 904

EP - 912

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 8

ER -